@article{13a27075b7f345e9afcbc9c06f924240,
title = "Germline BRCA variants, lifestyle and ovarian cancer survival",
abstract = "Objective: Women with ovarian cancer who have a pathogenic germline variant in BRCA1 or BRCA2 (BRCA) have been shown to have better 5-year survival after diagnosis than women who are BRCA-wildtype (non-carriers). Modifiable lifestyle factors, including smoking, physical activity and body mass index (BMI) have previously been associated with ovarian cancer survival; however, it is unknown whether these associations differ by germline BRCA status. Methods: We investigated measures of lifestyle prior to diagnosis in two cohorts of Australian women with invasive epithelial ovarian cancer, using Cox proportional hazards regression to calculate adjusted hazard ratios (HRs) and 95% confidence intervals (CIs). Results: In the combined studies (n = 1923), there was little association between physical activity, BMI or alcohol intake and survival, and no difference by BRCA status. However, the association between current smoking status before diagnosis and poorer survival was stronger for BRCA variant carriers (HR 1.98; 95% CI 1.20–3.27) than non-carriers (HR 1.18; 95% CI 0.96–1.46; p-interaction 0.02). We saw a similar differential association with smoking when we pooled results from two additional cohorts from the USA and UK (n = 2120). Combining the results from all four studies gave a pooled-HR of 1.94 (95% CI 1.28–2.94) for current smoking among BRCA variant carriers compared to 1.08 (0.90–1.29) for non-carriers. Conclusions: Our results suggest that the adverse effect of smoking on survival may be stronger for women with a BRCA variant than those without. Thus, while smoking cessation may improve outcomes for all women with ovarian cancer, it might provide a greater benefit for BRCA variant carriers.",
keywords = "BRCA1, BRCA2, Lifestyle, Ovarian cancer, Smoking, Survival",
author = "{the AOCS Group} and {the OPAL Study Group} and Kate Gersekowski and Rachel Delahunty and Kathryn Alsop and Goode, {Ellen L.} and Cunningham, {Julie M.} and Winham, {Stacey J.} and Paul Pharoah and Honglin Song and Susan Jordan and Sian Fereday and Anna DeFazio and Michael Friedlander and Andreas Obermair and Webb, {Penelope M.}",
note = "Funding Information: OCAC Funding: The Ovarian Cancer Association Consortium is funded by the generous contributions of its research investigators. It has also been supported by a grant from the Ovarian Cancer Research Fund thanks to donations by the family and friends of Kathryn Sladek Smith (PPD/RPCI.07). The scientific development and funding for this project were in part supported by the US National Cancer Institute GAME-ON Post-GWAS Initiative (U19-CA148112). This study made use of data generated by the Wellcome Trust Case Control consortium that was funded by the Wellcome Trust under award 076113.Funding for individual studies: The OPAL Study was funded by the National Health and Medical Research Council (NHMRC) of Australia (GNT1025142, GNT1120431); blood collection was partly funded by a grant from the Brisbane Women's Club. The Australian Ovarian Cancer Study Group was supported by the U.S. Army Medical Research and Materiel Command (DAMD17-01-1-0729), National Health & Medical Research Council of Australia (199600, 400413 and 400281), Cancer Councils of New South Wales, Victoria, Queensland, South Australia and Tasmania and Cancer Foundation of Western Australia (Multi-State Applications 191, 211 and 182). The Australian Ovarian Cancer Study gratefully acknowledges additional support from Ovarian Cancer Australia and the Peter MacCallum Foundation. Funding for BRCA testing was provided by the Australian Government (Public Health and Chronic Disease Grant Program), the US Department of Defense (W81XWH-08-1-0684 and W81XWH-08-1-0685), Cancer Australia (509303) and the Peter MacCallum Foundation. MAYO was funded by the National Institutes of Health (R01-CA122443, R01-CA248288, P50-CA136393). SEARCH was funded by Cancer Research UK (C490/A10119 C490/A10124); UK National Institute for Health Research Biomedical Research Centres at the University of Cambridge. University of Cambridge received salary support for PDPP from the NHS in the East of England through the Clinical Academic Reserve. PMW was supported by an NHMRC Fellowship (GNT1173346). Funding Information: PMW, AdF, KA and SF have received grant funding from AstraZeneca for an unrelated study of ovarian cancer. MF has received honoraria for advisory boards from AstraZeneca, MSD, Novartis, GlaxoSmithKline, Takeda and Lilly; research funding to his institution from AstraZeneca, BEIGENE and Novartis; travel expenses from AstraZeneca; and speakers fees from AstraZeneca, GSK and ACT Genomics. The other authors declare no potential conflicts of interest. Funding Information: OCAC Funding: The Ovarian Cancer Association Consortium is funded by the generous contributions of its research investigators. It has also been supported by a grant from the Ovarian Cancer Research Fund thanks to donations by the family and friends of Kathryn Sladek Smith ( PPD/RPCI.07 ). The scientific development and funding for this project were in part supported by the US National Cancer Institute GAME-ON Post-GWAS Initiative ( U19-CA148112 ). This study made use of data generated by the Wellcome Trust Case Control consortium that was funded by the Wellcome Trust under award 076113 . Funding Information: Funding for individual studies: The OPAL Study was funded by the National Health and Medical Research Council (NHMRC) of Australia ( GNT1025142 , GNT1120431 ); blood collection was partly funded by a grant from the Brisbane Women's Club. The Australian Ovarian Cancer Study Group was supported by the U.S. Army Medical Research and Materiel Command ( DAMD17-01-1-0729 ), National Health & Medical Research Council of Australia ( 199600 , 400413 and 400281), Cancer Councils of New South Wales, Victoria, Queensland , South Australia and Tasmania and Cancer Foundation of Western Australia (Multi-State Applications 191, 211 and 182). The Australian Ovarian Cancer Study gratefully acknowledges additional support from Ovarian Cancer Australia and the Peter MacCallum Foundation. Funding for BRCA testing was provided by the Australian Government ( Public Health and Chronic Disease Grant Program ), the US Department of Defense ( W81XWH-08-1-0684 and W81XWH-08-1-0685 ), Cancer Australia ( 509303 ) and the Peter MacCallum Foundation . MAYO was funded by the National Institutes of Health ( R01-CA122443 , R01-CA248288 , P50-CA136393 ). SEARCH was funded by Cancer Research UK ( C490/A10119 C490/A10124 ); UK National Institute for Health Research Biomedical Research Centres at the University of Cambridge . University of Cambridge received salary support for PDPP from the NHS in the East of England through the Clinical Academic Reserve . PMW was supported by an NHMRC Fellowship ( GNT1173346 ). Publisher Copyright: {\textcopyright} 2022 Elsevier Inc.",
year = "2022",
month = jun,
doi = "10.1016/j.ygyno.2022.03.020",
language = "English (US)",
volume = "165",
pages = "437--445",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "3",
}